© 2019 IPHARMA

  • Facebook Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon


IPHARMA got two Ministry of Health approvals for clinical trials conduction at once in December:

  • Phase III clinical study of the medical product OKITASK(Ketoprofen lysine salt)

  • Phase I clinical study of the medical product BI-MAB-03(Trastuzumab)

Medical produ...


The Quality Assurance Forum began its work in June 2017. This Forum assembled quality assurance experts in pharmaceutical industry for the exchange of experience and mutual support.

The first meeting of the Forum participants will be held on December 14, 2017.



On November 14-15, the 6th International Forum "Clinical trials in Russia" of the Adam Smith Institute was held in Moscow. IPHARMA was one of the major sponsors of the conference.

This year, a large pool of interesting speakers including representatives of the Federal S...


On November 13, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase II clinical study of the medicinal product AB5080.

Protocol FLU-AV5080-02 “Multicenter, randomized, double-blind, placebo-controlled study to assess effic...


In early November, IPHARMA received two approvals from the Ministry of Health of the Russian Federation to conduct phase I clinical trials of Ventvil® and Slavinorm® medicinal products.

Protocol № HEP-VTL-01 "A double-blind, randomized, placebo-controlled study of the s...


On November 14-16, XXI Russian Oncology Congress passed in Moscow. It is one of the largest international events in the field of oncology, in which more than 5,000 doctors take part annually.

Permanent organizers of the congress:

N.N. Blokhin Russian Cancer Research Cent...


On November 14-15 the sixth international conference of the Adam Smith Institute "Clinical Research in Russia" will be held. IPHARMA is one of the sponsors of the conference.

Under the program the latest regulatory changes, update the ICH GCP R2 standard, innovative str...


On October, 30 IPHARMA received the Ministry of Health permission to conduct Phase I trial of Hondrolux®

Protocol № ОА-CLX-01 “Double-blind, randomized, placebo-controlled study to access safety and tolerability of single and following multiple escalating doses of the K...


Adaptive design is an innovative approach that allows to conduct clinical trials more efficiently (with fewer patients, in shorter terms) or to increase the likelihood of demonstrating the effect of the drug. In studies with adaptation, the possibility of modifying a d...

Older news >

Please reload

Please reload